[Pubmed] Novel Immunotherapies for Myasthenia Gravis

[RSS-Bot]

Immunotargets Ther. 2023 Apr 4;12:25-45. doi: 10.2147/ITT.S377056. eCollection 2023.

ABSTRACT

Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades. Treatment-refractory MG and long-term toxicities of the medications have been major concerns with the conventional therapies. Advances in the immunology and pathogenesis of MG have ushered in an era of newer therapies which are more specific and efficacious. Complement inhibitors and neonatal Fc receptor blockers target disease-specific pathogenic mechanisms linked to myasthenia and have proven their efficacy in pivotal clinical studies. B cell-depleting agents, specifically rituximab, have also emerged as useful for the treatment of severe MG. Many more biologicals are in the pipeline and in diverse stages of development. This review discusses the evidence for the novel therapies and the specific issues related to their clinical use.

PMID:37038596 | PMC:PMC10082579 | DOI:10.2147/ITT.S377056


Source: https://pubmed.ncbi.nlm.nih.gov/3703859 ... t6+86293ac